Thilo Schroeder

Partner at Nextech Invest AG

Thilo Schroeder

Thilo Schroeder

Partner at Nextech Invest AG

Overview
RelSci Relationships

142

Number of Boards

5

Birthday

1982

Age

36

Relationships
RelSci Relationships are individuals Thilo Schroeder likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at ImaginAb, Inc.

Relationship likelihood: Strong

Partner at The Column Group LLC

Relationship likelihood: Strong

Senior Advisor to the President for Experimental Therapeutics at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Founder & Director at Peloton Therapeutics, Inc.

Relationship likelihood: Strong

Professor & Chairman-Biochemistry Department at The University of Texas - Southwestern Medical Center

Relationship likelihood: Strong

Chief Executive Officer at ImaginAb, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Peloton Therapeutics, Inc.

Relationship likelihood: Strong

President at Cedilla Therapeutics, Inc.

Relationship likelihood: Strong

Partner at Topspin Management LLC

Relationship likelihood: Strong

Founder at The Column Group LLC

Relationship likelihood: Strong

Paths to Thilo Schroeder
Potential Connections via
Relationship Science
You
Thilo Schroeder
Partner at Nextech Invest AG
Education
Ph.D. Biochemistry

The University of Zurich, located in the city of Zürich, is the largest university in Switzerland.

The Technische Universität (TU) Darmstadt is one of Germany’s leading technical universities. Its around 300 professors, 4,500 scientific and administrative employees and 26,000 students devote their talents and best efforts to the significant future research fields energy, mobility, communications and information technologies, housing and living conditions. The wide variety of disciplines represented are all focused on technology, as viewed from the vantage point of engineering, the natural sciences, the humanities, and the social sciences, and cover the full range of academic endeavor, from the origination of basic concepts to practical, everyday applications. The TU Darmstadt is Germany’s first autonomous university and has a state-funded budget of 200 million Euros (2012, incl. building funds). Its capacity for innovation is evidenced inter alia by the high level of annual funding received from outside sources. The 144.8 million Euros (2012, incl. LOEWE) contributed i.a. by industry, the Deutsche Forschungsgemeinschaft, and the European Union for 2012 make it one of Germany’s leading academic recipients of outside funding. In renowned rankings by the Deutsche Forschungsgemeinschaft, the Alexander von Humboldt Stiftung, and the Centrum für Hochschulentwicklung, as well as polls of the personnel directors of major corporations, it has consistently corroborated its leadership in research, academic excellence, and its qualification of graduates for top jobs and successful careers.

Career History
Partner
2012 - Current

Nextech is an active manager which invests in selected life science companies in Europe, Asia and the US. They have a particular focus on cancer therapy. They help build successful business ventures from life science innovations originating in academia and industry and also support the incubation of strong research teams.The firm seeks to invest in well managed companies with proprietary, cutting-edge products which understand the market and their competitors. Their investment approach aims to take drug assets in the preclinical stage and build their value by demonstrating clinical efficacy.Nextech mainly acts as lead investor in Europe and co-invests in OECD countries outside of Europe. They make investments based on recommendations from their Scientific Advisory Board, which assesses the scientific concept and the drug development plan.The firm aims to exit their investments through trade sales and IPOs after demonstrating efficacy or comparable benefits in human studies.

Professional
Prior

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A leader in biotechnology since 1980, Amgen was one of the first companies to realise the new science’s promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology, and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.

Boards & Committees
Director
2018 - Current

Revolution Medicines, Inc. develops new therapies derived from natural products. Its cancer biology platform focuses on undrugged tumor-intrinsic and immune system proteins. The firm specializes in atypical drug binding sites, mechanisms of action and allostery. The company was founded by Martin D. Burke and David L. Pompliano and Michael Fischbach in February 2015 and is headquartered in Redwood City, CA.

Member, Board of Directors
2018 - Current

IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. The company was founded by Yujiro S. Hata and Jeffrey Hager in 2015 and is headquartered in South San Francisco, CA.

Member, Board of Directors
Current

ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Thilo Schroeder. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Thilo Schroeder's profile does not indicate a business or promotional relationship of any kind between RelSci and Thilo Schroeder.